Altimmune (NASDAQ:ALT) Shares Gap Up – Still a Buy?

Altimmune, Inc. (NASDAQ:ALT) gapped up prior to trading on Tuesday . The stock had previously closed at $2.96, but opened at $3.16. Altimmune shares last traded at $3.07, with a volume of 6,413,156 shares changing hands.

More Altimmune News

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Altimmune announced that the 2.4 mg dose of pemvidutide achieved the primary endpoint in the RECLAIM Phase 2 trial, delivering a statistically significant and clinically meaningful reduction in heavy drinking days among patients with moderate-to-severe AUD. Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial
• Positive Sentiment: Key secondary measures also met, including a two-level reduction in World Health Organization drinking-risk categories and achieving zero heavy-drinking days—outcomes Altimmune said are recognized by the FDA as potential registrational endpoints. The drug’s tolerability profile was described as generally favorable. Altimmune Investigational Alcohol Use Disorder Drug Meets Primary Endpoint
• Positive Sentiment: The results broaden pemvidutide’s potential beyond Altimmune’s liver-disease programs and support management’s plans to advance the treatment toward later-stage development. Coverage characterized the trial outcome as an “unequivocal” mid-stage win, initially prompting a sharp move higher in ALT. Altimmune’s Next-Gen GLP-1 Phase 2 Alcohol Use Disorder Results
• Neutral Sentiment: Altimmune is also emphasizing momentum for pemvidutide ahead of a Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), its lead strategic focus. However, the AUD data remain topline Phase 2 results, with additional details and future trial plans still important for valuation. Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
• Negative Sentiment: After the initial rally, some investors may be taking profits while awaiting confirmatory Phase 3 evidence, regulatory guidance, and a clearer commercialization path. Altimmune remains an unprofitable clinical-stage biotech, so the stock continues to be highly sensitive to trial execution and funding risk.

Analyst Upgrades and Downgrades

ALT has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating on shares of Altimmune in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, June 24th. Citizens Jmp decreased their target price on Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Leerink Partners began coverage on Altimmune in a report on Monday, June 22nd. They set an “outperform” rating and a $10.00 target price for the company. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Altimmune currently has an average rating of “Moderate Buy” and a consensus target price of $15.71.

Altimmune Stock Performance

The stock has a 50 day simple moving average of $2.89 and a two-hundred day simple moving average of $3.51. The company has a market capitalization of $567.07 million, a price-to-earnings ratio of -3.14 and a beta of 0.25. The company has a debt-to-equity ratio of 0.12, a current ratio of 29.56 and a quick ratio of 29.56.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. As a group, analysts anticipate that Altimmune, Inc. will post -0.64 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

Several large investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. grew its position in shares of Altimmune by 156.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock worth $1,575,000 after acquiring an additional 316,209 shares during the last quarter. PVG Asset Management Corp acquired a new stake in shares of Altimmune during the first quarter worth about $204,000. Bank of America Corp DE boosted its stake in shares of Altimmune by 48.6% during the first quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after buying an additional 186,420 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Altimmune by 101.6% during the first quarter. EverSource Wealth Advisors LLC now owns 35,650 shares of the company’s stock worth $110,000 after buying an additional 17,967 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Altimmune by 26.0% during the first quarter. The Manufacturers Life Insurance Company now owns 34,763 shares of the company’s stock worth $107,000 after buying an additional 7,167 shares during the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.